药物的批准要求一个新药或者仿制药的递交和批准。
Approval of a drug requires the submission and approval of a new drug application or an abbreviated new drug application.
它的六种主要产品由五种将在今后四年面临仿制药的竞争。
Five of its six leading products face generic competition in the next four years.
我不否认制药的单位需要一定的利润，谁也不会去做无利可图的生意。
I do not deny that drug-manufacturing companies need to earn some profits.Otherwise, no one will undertake a non-profit business.
仿制药的生产和包装企业必须通过与那些品牌药相同的质量标准。
The generic manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs.
因为在辉瑞制药与百康制药的合作中显示，双方都可能需要合作伙伴。
As the Pfizer deal with Biocon suggests, both sides may need partners.
就是在桐君山上采药、制药的桐君老人，这座山也是以他的名字命名的。
It refers to Tong jun, who collected herbs and made medicines on the Tongjun Mountain, which was named after him.
是从事食品、保健品、生物制药的研究开发、生产和销售为一体的高科技企业。
Are engaged in food, health care products, bio-pharmaceutical research and development, production and sales of high-tech enterprises.
尽管中国具有增长潜力，但主要生产仿制药的国内企业，仍占据约四分之三的市场。
In spite of China's growth potential, local companies, which mainly produce generic drugs, still account for about three quarters of the market.
因此抗凝剂对于防治静脉血栓栓塞十分有效，而血小板功能抑制药的疗效则差一些。
Anticoagulants are therefore very effective for prevention and treatment of venous thromboembolism, and drugs that suppress platelet function are of less benefit.
其中仿制药的数量占到了全部处方药数量的65%，但是费用只占到总费用的大约20%。
Generics make up 65 percent of all prescriptions, but are roughly 20 percent of the costs.
像一些引进仿制药的大型制药公司，以及设备公司已经有很长一段时间没有对现有的产品做出改进。
Like Big Pharma, which introduced many "me too" drugs, device companies have sustained themselves by making small improvements to existing products.
像立普妥这样的拳头产品的专利过期时，来自仿制药的竞争使其价格暴跌，有时不足原价的十分之一。
When patents on blockbusters like Lipitor run out, generic competition ensures that prices collapse quickly-sometimes to a tenth of their former levels.
辉瑞制药的降血脂药立普妥(阿活他汀)，世界上销售最好的处方药，将在11月30日失支专利保护。
Lifetime sales of Pfizer's cholesterol-lowering drug Lipitor (atorvastatin), the world's top-selling prescription medicine. It loses patent protection from 30 November.
中国的政策支持会更进一步降低仿制药的价格，这会给药品研发机构及国际非专利药公司带来深远影响。
Chinese policy will drive generic prices down still further, with far-reaching consequences for both R&D players and international generic companies.
诺华制药的老总魏思乐博士坚决拥护近来的并购。但是也承认大公司现在必须去公司外找灵感，因为“我们无法面面俱到。”
Dr Vasella, Novartis's boss, stoutly defends recent mergers, but accepts that big firms must now look outside for inspiration because “we can't do it all ourselves.”
其中之一是利用一项旨在鼓励仿制药的法律。这项法律授予专利药物的第一个仿制品由监管机构批准的在美国6个月的垄断权。
One is a law intended to encourage generics that grants the first copy of a patented drug to win regulatory approval in America a six-month monopoly.
由此酝酿而生了一种局外人意识——对所有权威的极度不信任，从国会到媒体再到金融机构，甚至对垄断制药的大公司也不例外。
With that comes a sense of outsiderness — an intense distrust of allauthority, from Congress to the media to financial institutions, even themedical establishment.
然而，在通常情况下，第一个仿制药并不能在市场上自由的销售，因为专利所有人都会采取销售品牌药物的“授权”仿制药的措施进行干扰。
Often, however, the first generic does not have a free run, because patent-owners have taken to selling "authorised" generic versions of branded pills.
之所以想起这个课题，是由于我上周听说JeffKindler突然辞去了辉瑞制药的CEO职务，辞职的小部分原因是工作的压力影响到了他的生活。
I was reminded of this subject when I heard last week that Jeff Kindler had suddenly resigned as CEO of Pfizer, at least partly because the stresses of the job were affecting his family life.
一家于2008年转向生物仿制制药的美国制药公司---默克公司认为进入生物仿制制药这个领域的障碍是如此之大以至于“只有几家”公司有能力成功进入。
Michael Kamarck of Merck, an American drugs firm which moved into biosimilars in 2008, thinks the barriers to entry are so great that “only a handful” of firms will be able to pull it off.
根据派普和同事在《细胞》(Cell)期刊上发表的报告，因为与Medivation和辉瑞制药的实验性阿斯海默症治疗药物Dimebon 成份相似，这种化合物有可能提供更多改善该药药效的方法。
The compound is similar to Medivation Inc and Pfizer Inc's experimental Alzheimer's drug, Dimebon, and may provide ways to improve its effects, Pieper and colleagues reported in the journal Cell.
底线是，制药公司整体上在市场营销上的投资要多于在研发上的投资。
The bottom line is that pharmaceutical companies as a whole invest more in marketing than they do in research and development.
“它为制药行业松绑，这样他们就可以开始治疗这种疾病，而不仅仅是疾病的副作用。”他说。
"It unties the hands of the pharmaceutical industry so that they can begin treating the disease and not just the side effects," he said.
这为制药行业松绑，这样，他们就可以开始治疗这种疾病，而不仅仅是治疗疾病的副作用。
It unties the hands of the pharmaceutical industry so that they can begin treating the disease and not just the side effects.
应用推荐